The CARE study and cardiovascular calcification

Area of Science:

• Nephrology
• Cardiology
• Mineral Metabolism

Background:

• Cardiovascular disease (CVD) causes nearly 50% of deaths in dialysis patients.
• Abnormalities in mineral metabolism, particularly hyperphosphatemia, contribute significantly to CVD risk.
• Hyperphosphatemia is common in end-stage renal disease (ESRD) and linked to increased mortality.

Purpose of the Study:

• To review the role of hyperphosphatemia in CVD pathogenesis in dialysis patients.
• To evaluate the efficacy and safety of calcium acetate as a phosphate binder.
• To assess calcium acetate's impact on cardiovascular calcification in the context of K/DOQI guidelines.

Main Methods:

• Literature review of studies on mineral metabolism, CVD, and phosphate binders in dialysis patients.
• Analysis of data regarding calcium acetate and sevelamer efficacy and cost-effectiveness.
• Examination of evidence linking phosphate binders to cardiovascular calcification.

Main Results:

• Hyperphosphatemia is a critical factor in CVD and mortality risk in dialysis patients.
• Calcium acetate is a cost-effective phosphate binder compared to sevelamer.
• Evidence suggests calcium acetate can be used safely, meeting K/DOQI guidelines for elemental calcium, without exacerbating cardiovascular calcification.

Conclusions:

• Effective management of serum phosphorus and calcium-x-phosphorus product is crucial for improving outcomes in dialysis patients.
• Calcium acetate presents a viable and cost-effective option for phosphate control.
• Further research may clarify the precise mechanisms linking mineral metabolism and CVD in ESRD.